Haichuang Pharmaceutical announced that the company received a notice from the US Food and Drug Administration, and the clinical trial application for HP570 tablets independently developed by the company to treat rheumatoid arthritis was officially approved by the FDA.

Haichuang Pharmaceutical announced that the company received a notice from the US Food and Drug Administration, and the clinical trial application for HP570 tablets independently developed by the company to treat rheumatoid arthritis was officially approved by the FDA.